UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 10, 2022
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||
(Address of principal executive offices) (Zip code)
Registrant’s telephone number, including area code: 781 -848-7100
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): | |||||
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
| Securities registered pursuant to Section 12(b) of the Act: | ||||||||
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
| Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). | ||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ | ||
Item 2.02 Results of Operations and Financial Condition.
On May 10, 2022 , Haemonetics Corporation issued a press release announcing financial results for the fourth quarter and year ended April 2, 2022. A copy of the release is furnished with this report as Exhibit 99.1.
The foregoing information, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit Number | Description | |||||||
Press Release of Haemonetics Corporation dated | ||||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| HAEMONETICS CORPORATION | ||||||||||||||
| Date : May 10, 2022 | By: | /s/ Christopher A. Simon | ||||||||||||
| Name: | Christopher A. Simon | |||||||||||||
| Title: | President and Chief Executive Officer | |||||||||||||
| Exhibit 99.1 | |||||
| Investor Contact | Media Contact | ||||
| Olga Guyette, Sr. Director-Investor Relations & Treasury | Josh Gitelson, Director-Communications | ||||
| (781) 356-9763 | (781) 356-9776 | ||||
| olga.guyette@haemonetics.com | josh.gitelson@haemonetics.com | ||||
Haemonetics Reports Fourth Quarter and Fiscal 2022 Results;
Provides Fiscal 2023 Guidance
Boston, MA, May 10, 2022 - Haemonetics Corporation (NYSE: HAE) reported financial results for its fourth quarter and fiscal 2022, which ended April 2, 2022:
| 4th Quarter 2022 | Fiscal 2022 | ||||||||||
■Revenue, increase | $265 million, 18% | $993 million, 14% | |||||||||
■Organic1 revenue increase | 19% | 7% | |||||||||
■Earnings per diluted share | $0.19 | $0.84 | |||||||||
■Adjusted earnings per diluted share | $0.65 | $2.58 | |||||||||
■Cash flow from operating activities | $68 million | $172 million | |||||||||
■Free cash flow before restructuring & restructuring related costs | $42 million | $117 million | |||||||||
1Excludes the impact of currency fluctuation, strategic exits of product lines, acquisitions and divestitures and the impact of the 53rd week in fiscal 2021. | |||||||||||
Chris Simon, Haemonetics’ CEO, stated: "Our fourth quarter performance is a culmination of a fiscal year in which we strengthened and grew our business despite pandemic challenges. We supported plasma recovery through our NexSys and Persona technologies, served customers in need in Blood Center, and delivered robust growth in Hospital, including another record sales quarter in Vascular Closure. Our Operational Excellence Program enabled us to respond quickly to supply chain disruptions and mitigate inflationary pressures. We are well positioned to build upon our momentum in Fiscal 2023 and beyond."
GAAP RESULTS
Fourth quarter fiscal 2022 revenue was $265.0 million, up 17.8% compared with the same period of fiscal 2021. Business unit revenue and growth rates compared with the prior year period were as follows:
| ($ millions) | 4th Quarter 2022 Reported | ||||||||||
| Plasma | $ 101.1 | 20.8% | |||||||||
| Hospital | $ 85.8 | 37.9% | |||||||||
| Blood Center | $ 73.1 | (0.9%) | |||||||||
| Net business unit revenue | $260.0 | 18.3% | |||||||||
| Service | $ 5.0 | (5.9%) | |||||||||
| Total net revenue | $265.0 | 17.8% | |||||||||
1
Gross margin was 51.4% in the fourth quarter of fiscal 2022, compared with 36.4% in the fourth quarter of fiscal 2021. Operating expenses were $117.1 million in the fourth quarter of fiscal 2022, compared with $103.0 million in the fourth quarter of fiscal 2021. The Company had operating income of $19.2 million and a 7.2% operating margin in the fourth quarter of fiscal 2022, compared with an operating loss of $21.2 million and an operating margin of (9.4)% in the fourth quarter of fiscal 2021. The income tax rates were 36% and (60%) in the fourth quarters of fiscal 2022 and fiscal 2021, respectively. Fourth quarter fiscal 2022 net income and earnings per diluted share were $9.7 million and $0.19, respectively, compared with a net loss and net loss per share of $11.0 million and $0.22, respectively, in the fourth quarter of fiscal 2021.
ADJUSTED RESULTS
Organic revenue for the fourth quarter of fiscal 2022 was up 18.9% compared with the same prior year period of fiscal 2021. Business unit organic revenue growth rates compared with the prior year period were as follows:
4th Quarter 2022 Organic | |||||
| Plasma | 30.6% | ||||
| Hospital | 18.6% | ||||
| Blood Center | 7.5% | ||||
| Net business unit revenue | 19.5% | ||||
| Service | (3.9%) | ||||
| Total net revenue | 18.9% | ||||
Within Hospital, organic revenue growth in the Hemostasis Management product line was 11.9% in the fourth quarter of fiscal 2022 compared with the same period of fiscal 2021.
Fourth quarter fiscal 2022 adjusted gross margin was 53.6%, up 360 basis points compared with the prior year period. The primary drivers of this improvement were the acquisition of our Vascular Closure business, price and productivity savings from the Operational Excellence Program, partially offset by inflationary pressures in our global manufacturing and supply chain and increased depreciation expense.
Adjusted operating expenses in the fourth quarter of fiscal 2022 were $95.4 million, up $13.4 million, or 16.4%, compared with the prior year period. The increase in adjusted operating expenses was primarily driven by the acquisition of our Vascular Closure business and an increase in freight costs. Adjusted operating income for the fourth quarter of fiscal 2022 was $46.6 million, up $16.1 million or 52.8%, and adjusted operating margin was 17.6%, up 410 basis points when compared with the same period of fiscal 2021. The adjusted income tax rate was 22% in the fourth quarter of fiscal 2022 compared with an adjusted income tax rate of 12% in the fourth quarter of fiscal 2021.
Fourth quarter fiscal 2022 adjusted net income was $33.5 million, up $9.6 million or 40.3%, and adjusted earnings per diluted share was $0.65, up 41.3%, each when compared with the same period of fiscal 2021.
2
RESTRUCTURING AND RESTRUCTURING RELATED COSTS, DEAL AMORTIZATION AND CERTAIN OTHER COSTS
The Company incurred restructuring and restructuring related costs of $8.6 million in the fourth quarter of fiscal 2022 compared with $4.1 million in the fourth quarter of fiscal 2021 and deal amortization expenses of $11.5 million in the fourth quarter of fiscal 2022 compared with $8.6 million in the fourth quarter of fiscal 2021.
In addition, during the fourth quarter of fiscal 2022, the Company incurred $3.9 million of costs related to compliance with the European Union Medical Device Regulation and In Vitro Diagnostic Regulation, as compared with $1.4 million of such costs in the fourth quarter of fiscal 2021.
BALANCE SHEET AND CASH FLOW
Cash on hand at April 2, 2022 was $259.5 million, an increase of $67.2 million since April 3, 2021. During fiscal 2022, the Company had debt repayments of $17.5 million and received $10.6 million of cash from earnout payments associated with a divestiture in fiscal 2021.
Cash flow from operating activities was $172.3 million and free cash flow before restructuring and restructuring related costs was $117.4 million during fiscal 2022, compared with $108.8 million and $99.2 million, respectively, in fiscal 2021. During fiscal 2021, cash flow from operating activities and free cash flow before restructuring and restructuring related costs included a $54.3 million payment for a compensation-related liability as part of the Cardiva Medical acquisition.
FISCAL 2023 GUIDANCE
The Company issued its fiscal 2023 GAAP total revenue growth guidance of 5 – 9% and organic revenue growth guidance as follows:
Organic1 | |||||
| Total revenue | 6 - 10% | ||||
| Plasma revenue | 7 - 12% | ||||
| Hospital Revenue | 16 - 19% | ||||
| Blood Center revenue | (4 - 7%) | ||||
1Excludes the impact of currency fluctuation and strategic exits of product lines. Reconciliations of reported to organic revenue are provided in the schedules accompanying this release and in the analytical tables referenced below. | |||||
Additionally, the Company issued its adjusted operating margin, adjusted earnings per diluted share and free cash flow before restructuring and restructuring related costs guidance as follows:
| Adjusted operating margin | 18 - 19% | ||||
| Adjusted earnings per diluted share | $2.50 - $2.90 | ||||
| Free cash flow, before restructuring & restructuring related costs | $100M - $130M | ||||
3
WEBCAST CONFERENCE CALL AND RESULTS ANALYSIS
The Company will host a conference call with investors and analysts to discuss fourth quarter and full year fiscal 2022 results on Tuesday, May 10, 2022 at 8:00am EDT. Interested parties may participate by telephone by dialing (877) 848-8880 from within the U.S. or Canada or (716) 335-9512 from international locations, using the access code 5347317. Alternatively, a live webcast of the call can be accessed on Haemonetics’ investor relations website at the following direct link: https://edge.media-server.com/mmc/p/gooqch6s
The Company is posting this press release to its Investor Relations website, in addition to supplemental analytical tables that will be referenced on the webcast. These supplemental analytical tables can be accessed at the following direct link: https://haemonetics.gcs-web.com/static-files/52e9f8bf-c0fc-490a-af79-5fe4fef86e06
ABOUT HAEMONETICS
Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.
FORWARD-LOOKING STATEMENTS
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements in this press release may include, without limitation, statements regarding (i) plans and objectives of management for operations of the Company, including plans or objectives related to the development and commercialization of, and regulatory approvals related to, the Company’s products and plans or objectives related to the Operational Excellence Program; (ii) estimates or projections of financial results, financial condition, capital expenditures, capital structure or other financial items, (iii) the impact of the COVID-19 pandemic and associated inflationary pressures on the Company’s operations, availability and demand for its products, and future financial performance, and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the impact of the COVID-19 pandemic, including its scope and duration (including the extent of future surges, variants and the efficacy of vaccinations), government actions and restrictive measures implemented in response and associated economic disruptions, including inflationary pressures and higher freight costs in our global supply chain; availability and demand for the Company’s products; the Company’s ability to
4
implement as planned and realize estimated cost savings from the Operational Excellence Program; the Company’s ability to execute business continuity plans; risks arising from planned or completed acquisitions or divestitures by the Company, including any failure to realize the anticipated strategic benefits and opportunities of the transaction; technological advances in the medical field and standards for transfusion medicine and the Company’s ability to successfully offer products that incorporate such advances and standards; product quality; market acceptance; regulatory uncertainties, including in the receipt or timing of regulatory approvals; the effect of economic and political conditions; the impact of competitive products and pricing; blood product reimbursement policies and practices; and the effect of industry consolidation as seen in the plasma market. These and other factors are identified and described in more detail in the Company’s periodic reports and other filings with the U.S. Securities and Exchange Commission (the “SEC”). The Company does not undertake to update these forward-looking statements.
MANAGEMENT’S USE OF NON-GAAP MEASURES
This press release contains financial measures that are considered “non-GAAP” financial measures under applicable SEC rules and regulations. Management uses non-GAAP measures to monitor the financial performance of the business, make informed business decisions, establish budgets and forecast future results. Performance targets for management are also based on certain non-GAAP financial measures. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, the Company’s reported financial results prepared in accordance with U.S. GAAP. In this release, supplemental non-GAAP measures have been provided to assist investors in evaluating the performance of the Company’s core operations and provide a baseline for analyzing trends in the Company’s underlying businesses. We strongly encourage investors to review the Company’s financial statements and publicly-filed reports in their entirety and not rely on any single financial measure.
When used in this release, organic revenue growth excludes the impact of currency fluctuation, strategic exits of product lines, acquisitions and divestitures and the impact of the 53rd week in fiscal 2021. Adjusted gross profit, adjusted operating expenses, adjusted operating income, adjusted net income and adjusted earnings per diluted share exclude restructuring and restructuring related costs, deal amortization expenses, asset impairments, accelerated device depreciation and related costs, costs related to compliance with the European Union Medical Device Regulation and In Vitro Diagnostic Regulation, integration and transaction costs, gains and losses on dispositions, certain tax settlements and unusual or infrequent and material litigation-related charges. Adjusted net income and adjusted earnings per diluted share also exclude the tax impact of these items. Free cash flow before restructuring and restructuring related costs is defined as cash provided by operating activities less capital expenditures, net of the proceeds from the sale of property, plant and equipment. Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures to similarly titled measures used by other companies.
A reconciliation of non-GAAP historical financial measures to their most comparable GAAP measure are included at the end of the financial sections of this press release as well as on the Company’s website at www.haemonetics.com. The Company does not provide a quantitative reconciliation of its forward-looking organic revenue growth guidance by business unit to the
5
comparable GAAP measure because forecasting the impact of foreign currency fluctuations by business unit is inherently uncertain and difficult to predict and is unavailable without unreasonable efforts. Additionally, the Company does not attempt to provide reconciliations of forward-looking adjusted operating margin guidance, adjusted earnings per diluted share guidance or free cash flow before restructuring and restructuring related costs guidance to the comparable GAAP measures because the combined impact and timing of recognition of certain potential charges or gains, such as restructuring costs and impairment charges, is inherently uncertain and difficult to predict and is unavailable without unreasonable efforts. In addition, the Company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a substantial impact on GAAP measures of the Company’s financial performance.
6
| Haemonetics Corporation Financial Summary | ||||||||||||||||||||
| Condensed Consolidated Statements of Income (Loss) for the Fourth Quarter of FY22 and FY21 | ||||||||||||||||||||
| (Data in thousands, except per share data) | ||||||||||||||||||||
| 4/2/2022 | 4/3/2021 | % Inc/(Dec) | ||||||||||||||||||
| vs Prior Year | ||||||||||||||||||||
| (unaudited) | ||||||||||||||||||||
| Net revenues | $ | 265,002 | $ | 225,029 | 17.8% | |||||||||||||||
| Gross profit | 136,311 | 81,807 | 66.6% | |||||||||||||||||
| R&D | 13,210 | 10,843 | 21.8% | |||||||||||||||||
| S,G&A | 91,841 | 83,712 | 9.7% | |||||||||||||||||
| Amortization of intangible assets | 11,484 | 8,626 | 33.1% | |||||||||||||||||
| Impairment of assets | 577 | — | n/m | |||||||||||||||||
| Gains on divestitures and sale of assets | — | (199) | n/m | |||||||||||||||||
| Operating expenses | 117,112 | 102,982 | 13.7% | |||||||||||||||||
| Operating income (loss) | 19,199 | (21,175) | n/m | |||||||||||||||||
| Interest and other expense, net | (3,872) | (6,222) | (37.8)% | |||||||||||||||||
| Income (loss) before taxes | 15,327 | (27,397) | n/m | |||||||||||||||||
| Tax expense (benefit) | 5,586 | (16,356) | n/m | |||||||||||||||||
| Net income (loss) | $ | 9,741 | $ | (11,041) | n/m | |||||||||||||||
| Net income (loss) per common share assuming dilution | $ | 0.19 | $ | (0.22) | n/m | |||||||||||||||
| Weighted average number of shares: | ||||||||||||||||||||
| Basic | 51,117 | 50,848 | ||||||||||||||||||
| Diluted | 51,354 | 50,848 | ||||||||||||||||||
| Profit Margins: | Inc/(Dec) vs prior year profit margin % | |||||||||||||||||||
| Gross profit | 51.4 | % | 36.4 | % | 15.0% | |||||||||||||||
| R&D | 5.0 | % | 4.8 | % | 0.2% | |||||||||||||||
| S,G&A | 34.7 | % | 37.2 | % | (2.5)% | |||||||||||||||
| Operating income (loss) | 7.2 | % | (9.4) | % | 16.6% | |||||||||||||||
| Income (loss) before taxes | 5.8 | % | (12.2) | % | 18.0% | |||||||||||||||
| Net income (loss) | 3.7 | % | (4.9) | % | 8.6% | |||||||||||||||
7
| Haemonetics Corporation Financial Summary | ||||||||||||||||||||
| Condensed Consolidated Statements of Income for Year-to-Date FY22 and FY21 | ||||||||||||||||||||
| (Data in thousands, except per share data) | ||||||||||||||||||||
| 4/2/2022 | 4/3/2021 | % Inc/(Dec) | ||||||||||||||||||
| vs Prior Year | ||||||||||||||||||||
| (unaudited) | ||||||||||||||||||||
| Net revenues | $ | 993,196 | $ | 870,463 | 14.1% | |||||||||||||||
| Gross profit | 505,502 | 397,838 | 27.1% | |||||||||||||||||
| R&D | 46,801 | 32,857 | 42.4% | |||||||||||||||||
| S,G&A | 339,563 | 274,188 | 23.8% | |||||||||||||||||
| Amortization of intangible assets | 47,414 | 32,830 | 44.4% | |||||||||||||||||
| Impairment of assets | 577 | 1,028 | (43.9)% | |||||||||||||||||
| Gains on divestitures and sale of assets | (9,603) | (32,812) | (70.7)% | |||||||||||||||||
| Operating expenses | 424,752 | 308,091 | 37.9% | |||||||||||||||||
| Operating income | 80,750 | 89,747 | (10.0)% | |||||||||||||||||
| Interest and other expense, net | (17,121) | (16,834) | 1.7% | |||||||||||||||||
| Income before taxes | 63,629 | 72,913 | (12.7)% | |||||||||||||||||
| Tax expense (benefit) | 20,254 | (6,556) | n/m | |||||||||||||||||
| Net income | $ | 43,375 | $ | 79,469 | (45.4)% | |||||||||||||||
| Net income per common share assuming dilution | $ | 0.84 | $ | 1.55 | (45.8)% | |||||||||||||||
| Weighted average number of shares: | ||||||||||||||||||||
| Basic | 51,047 | 50,688 | ||||||||||||||||||
| Diluted | 51,353 | 51,292 | ||||||||||||||||||
| Profit Margins: | Inc/(Dec) vs prior year profit margin % | |||||||||||||||||||
| Gross profit | 50.9 | % | 45.7 | % | 5.2% | |||||||||||||||
| R&D | 4.7 | % | 3.8 | % | 0.9% | |||||||||||||||
| S,G&A | 34.2 | % | 31.5 | % | 2.7% | |||||||||||||||
| Operating income | 8.1 | % | 10.3 | % | (2.2)% | |||||||||||||||
| Income before taxes | 6.4 | % | 8.4 | % | (2.0)% | |||||||||||||||
| Net income | 4.4 | % | 9.1 | % | (4.7)% | |||||||||||||||
8
| Revenue Analysis for the Fourth Quarter of FY22 and FY21 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| (Data in thousands) | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Three Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||
| 4/2/2022 | 4/3/2021 | Reported growth | Currency impact | Acquisition and Divestitures(1) | Other Strategic Exits(2) | 53rd Week | Organic Growth | |||||||||||||||||||||||||||||||||||||||||||
| (unaudited) | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Revenues by business unit | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Plasma | $ | 101,103 | $ | 83,683 | 20.8 | % | (0.3) | % | — | % | (0.8) | % | (8.7) | % | 30.6 | % | ||||||||||||||||||||||||||||||||||
| Blood Center | 73,133 | 73,830 | (0.9) | % | (1.1) | % | — | % | — | % | (7.3) | % | 7.5 | % | ||||||||||||||||||||||||||||||||||||
Hospital (3) | 85,730 | 62,164 | 37.9 | % | (1.5) | % | 24.7 | % | — | % | (3.9) | % | 18.6 | % | ||||||||||||||||||||||||||||||||||||
| Net business unit revenues | $ | 259,966 | $ | 219,677 | 18.3 | % | (0.9) | % | 0.8 | % | (0.1) | % | (1.0) | % | 19.5 | % | ||||||||||||||||||||||||||||||||||
| Service | 5,036 | 5,352 | (5.9) | % | (2.0) | % | — | % | — | % | — | % | (3.9) | % | ||||||||||||||||||||||||||||||||||||
| Total net revenues | $ | 265,002 | $ | 225,029 | 17.8 | % | (1.0) | % | 0.8 | % | — | % | (0.9) | % | 18.9 | % | ||||||||||||||||||||||||||||||||||
(1) Reflects the impact in Hospital related to the acquisition of Vascular Closure from Cardiva Medical Inc. (2) Reflects adjustments to both fiscal 2022 and 2021 Plasma revenue due to certain strategic exits within the liquid solutions business. (3) Hospital revenue includes Hemostasis Management revenue of $30.2 million and $28.9 million for the three months ended April 2, 2022 and April 3, 2021, respectively. Hemostasis Management revenue increased 4.5% in the fourth quarter of fiscal 2022 as compared with the same period of fiscal 2021. Hemostasis Management revenue increased 11.9%, on an organic basis, in the fourth quarter of fiscal 2022 as compared with the same period of fiscal 2021. Hospital revenue also includes Vascular Closure revenue of $27.0 million and $7.7 million for the three months ended April 2, 2022 and April 3, 2021, respectively. Vascular Closure revenue is included in the organic revenue growth rate beginning March 2022. | ||||||||||||||||||||||||||||||||||||||||||||||||||
9
| Revenue Analysis for Year-to-Date FY22 and FY21 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| (Data in thousands) | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Year Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||
| 4/2/2022 | 4/3/2021 | Reported growth | Currency impact | Acquisition and Divestitures(1) | Other Strategic Exits(2) | 53rd Week | Organic Growth | |||||||||||||||||||||||||||||||||||||||||||
| (unaudited) | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Revenues by business unit | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Plasma | $ | 351,347 | $ | 332,236 | 5.8 | % | 0.2 | % | — | % | (2.3) | % | (1.8) | % | 9.7 | % | ||||||||||||||||||||||||||||||||||
| Blood Center | 298,512 | 307,452 | (2.9) | % | 1.3 | % | (1.2) | % | — | % | (1.6) | % | (1.4) | % | ||||||||||||||||||||||||||||||||||||
Hospital (3) | 322,804 | 210,632 | 53.3 | % | 0.6 | % | 37.7 | % | — | % | (1.2) | % | 16.2 | % | ||||||||||||||||||||||||||||||||||||
| Net business unit revenues | $ | 972,663 | $ | 850,320 | 14.4 | % | 0.7 | % | 8.7 | % | (0.8) | % | (1.5) | % | 7.3 | % | ||||||||||||||||||||||||||||||||||
| Service | 20,533 | 20,143 | 1.9 | % | 1.6 | % | — | % | — | % | — | % | 0.3 | % | ||||||||||||||||||||||||||||||||||||
| Total net revenues | $ | 993,196 | $ | 870,463 | 14.1 | % | 0.7 | % | 8.7 | % | (0.9) | % | (1.5) | % | 7.1 | % | ||||||||||||||||||||||||||||||||||
(1) Reflects the impacts in Blood Center of (0.8%) and (0.4%) related to the divestitures of the Company’s U.S. blood donor management software solutions assets and of Inlog, respectively. Also reflects the impacts in Hospital of 38.8% related to the acquisition of Vascular Closure from Cardiva Medical Inc. and of (1.2%) related to the divestiture of InLog. (2) Reflects adjustments to both fiscal 2022 and 2021 Plasma revenue due to certain strategic exits within the liquid solutions business. (3) Hospital revenue includes Hemostasis Management revenue of $127.4 million and $107.4 million for the years ended April 2, 2022 and April 3, 2021, respectively. Hemostasis Management revenue increased 18.6% in fiscal 2022 as compared with fiscal 2021. Hemostasis Management revenue increased 20.3%, on an organic basis, in fiscal 2022 as compared with fiscal 2021. Hospital revenue also includes Vascular Closure revenue of $93.8 million and $7.7 million for the years ended April 2, 2022 and April 3, 2021, respectively. Vascular Closure revenue is included in the organic revenue growth rate beginning March 2022. | ||||||||||||||||||||||||||||||||||||||||||||||||||
10
| Condensed Consolidated Balance Sheets | |||||||||||||||||
| (Data in thousands) | |||||||||||||||||
| As of | |||||||||||||||||
| 4/2/2022 | 4/3/2021 | ||||||||||||||||
| (unaudited) | |||||||||||||||||
| Assets | |||||||||||||||||
| Cash and cash equivalents | $ | 259,496 | $ | 192,305 | |||||||||||||
| Accounts receivable, net | 159,376 | 127,555 | |||||||||||||||
| Inventories, net | 293,027 | 322,614 | |||||||||||||||
| Other current assets | 44,132 | 51,072 | |||||||||||||||
| Total current assets | 756,031 | 693,546 | |||||||||||||||
| Property, plant & equipment, net | 258,482 | 217,559 | |||||||||||||||
| Intangible assets, net | 310,261 | 365,483 | |||||||||||||||
| Goodwill | 467,287 | 466,444 | |||||||||||||||
| Other assets | 67,673 | 76,891 | |||||||||||||||
| Total assets | $ | 1,859,734 | $ | 1,819,923 | |||||||||||||
| Liabilities & Stockholders' Equity | |||||||||||||||||
| Short-term debt & current maturities | $ | 214,148 | $ | 17,016 | |||||||||||||
| Other current liabilities | 228,118 | 236,479 | |||||||||||||||
| Total current liabilities | 442,266 | 253,495 | |||||||||||||||
| Long-term debt | 559,441 | 690,592 | |||||||||||||||
| Other long-term liabilities | 108,603 | 144,166 | |||||||||||||||
| Stockholders' equity | 749,424 | 731,670 | |||||||||||||||
| Total liabilities & stockholders' equity | $ | 1,859,734 | $ | 1,819,923 | |||||||||||||
11
| Condensed Consolidated Statements of Cash Flows | |||||||||||
| (Data in thousands) | |||||||||||
| Year Ended | |||||||||||
| 4/2/2022 | 4/3/2021 | ||||||||||
| (unaudited) | |||||||||||
| Cash Flows from Operating Activities: | |||||||||||
| Net income | $ | 43,375 | $ | 79,469 | |||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||||||||
| Depreciation and amortization | 97,747 | 84,287 | |||||||||
| Contingent consideration expense | 10,461 | — | |||||||||
| Share-based compensation expense | 24,359 | 25,516 | |||||||||
| Amortization of fair value inventory step-up | 5,295 | — | |||||||||
| Impairment of assets | 7,953 | 21,969 | |||||||||
| Gains on divestitures and sale of assets | (9,603) | (32,812) | |||||||||
| Change in other non-cash operating activities | 7,853 | (9,942) | |||||||||
| Change in accounts receivable, net | (34,974) | 44,121 | |||||||||
| Change in inventories | 24,307 | (38,909) | |||||||||
| Change in other working capital | (4,510) | (64,894) | |||||||||
| Net cash provided by operating activities | 172,263 | 108,805 | |||||||||
| Cash Flows from Investing Activities: | |||||||||||
| Capital expenditures | (96,509) | (37,040) | |||||||||
| Acquisitions | (2,500) | (434,804) | |||||||||
| Proceeds from sale of property, plant and equipment | 2,022 | 1,815 | |||||||||
| Proceeds from divestitures | 10,642 | 44,587 | |||||||||
| Net cash used in investing activities | (86,345) | (425,442) | |||||||||
| Cash Flows from Financing Activities: | |||||||||||
| Proceeds from issuance of convertible notes | — | 500,000 | |||||||||
| Purchase of capped call related to convertible notes | — | (47,400) | |||||||||
| Transaction costs paid in connection with convertible notes issuance | — | (13,457) | |||||||||
| Repayments of debt | (17,500) | (81,875) | |||||||||
| Proceeds from employee stock programs | 6,547 | 10,230 | |||||||||
| Contingent consideration payments | (4,791) | — | |||||||||
| Other | (5) | (46) | |||||||||
| Net cash (used in) provided by in financing activities | (15,749) | 367,452 | |||||||||
| Effect of exchange rates on cash and cash equivalents | (2,978) | 4,179 | |||||||||
| Net Change in Cash and Cash Equivalents | 67,191 | 54,994 | |||||||||
| Cash and Cash Equivalents at Beginning of the Period | 192,305 | 137,311 | |||||||||
| Cash and Cash Equivalents at End of Period | $ | 259,496 | $ | 192,305 | |||||||
| Free Cash Flow Reconciliation: | |||||||||||
| Cash provided by operating activities | $ | 172,263 | $ | 108,805 | |||||||
| Capital expenditures, net of proceeds from sale of property, plant and equipment | (94,487) | (35,225) | |||||||||
| Free cash flow after restructuring and restructuring related costs | $ | 77,776 | $ | 73,580 | |||||||
| Restructuring and restructuring related costs | 50,193 | 32,639 | |||||||||
| Tax benefit on restructuring and restructuring related costs | (10,532) | (7,017) | |||||||||
| Free cash flow before restructuring and restructuring related costs | $ | 117,437 | $ | 99,202 | |||||||
12
| Reconciliation of Adjusted Measures for the Fourth Quarter of FY22 and FY21 | |||||||||||
| (Data in thousands except per share data) | |||||||||||
| Three Months Ended | |||||||||||
| 4/2/2022 | 4/3/2021 | ||||||||||
| (unaudited) | |||||||||||
| GAAP gross profit | $ | 136,311 | $ | 81,807 | |||||||
| Restructuring and restructuring related costs | 5,330 | 2,869 | |||||||||
| Integration and transaction costs | — | 6,471 | |||||||||
| Impairment of assets and PCS2 related charges | 329 | 21,276 | |||||||||
| Adjusted gross profit | $ | 141,970 | $ | 112,423 | |||||||
| GAAP operating expenses | $ | 117,112 | $ | 102,982 | |||||||
| Deal amortization | (11,484) | (8,626) | |||||||||
| Integration and transaction costs | (2,386) | (8,887) | |||||||||
MDR and IVDR costs(1) | (3,863) | (1,434) | |||||||||
| Restructuring and restructuring related costs | (3,243) | (1,209) | |||||||||
| Litigation-related charges | (147) | (897) | |||||||||
| Impairment of assets and PCS2 related charges | (613) | (192) | |||||||||
| Gain on divestitures and sale of assets | — | 199 | |||||||||
| Adjusted operating expenses | $ | 95,376 | $ | 81,936 | |||||||
| GAAP operating income (loss) | $ | 19,199 | $ | (21,175) | |||||||
| Deal amortization | 11,484 | 8,626 | |||||||||
| Integration and transaction costs | 2,386 | 15,358 | |||||||||
| Restructuring and restructuring related costs | 8,573 | 4,078 | |||||||||
| Impairment of assets and PCS2 related charges | 942 | 21,468 | |||||||||
MDR and IVDR costs(1) | 3,863 | 1,434 | |||||||||
| Litigation-related charges | 147 | 897 | |||||||||
| Gain on divestitures and sale of assets | — | (199) | |||||||||
| Adjusted operating income | $ | 46,594 | $ | 30,487 | |||||||
| GAAP net income (loss) | $ | 9,741 | $ | (11,041) | |||||||
| Deal amortization | 11,484 | 8,626 | |||||||||
| Integration and transaction costs | 2,386 | 18,328 | |||||||||
| Restructuring and restructuring related costs | 8,573 | 4,078 | |||||||||
| Impairment of assets and PCS2 related charges | 942 | 21,468 | |||||||||
MDR and IVDR costs(1) | 3,863 | 1,434 | |||||||||
| Litigation-related charges | 147 | 897 | |||||||||
| Tax settlement | — | 1,083 | |||||||||
| Gain on divestitures and sale of assets | — | (199) | |||||||||
| Tax impact associated with adjustments | (3,604) | (20,782) | |||||||||
| Adjusted net income | $ | 33,532 | $ | 23,892 | |||||||
GAAP net income (loss) per common share(2) | $ | 0.19 | $ | (0.22) | |||||||
| Adjusted items after tax per common share assuming dilution | 0.46 | 0.68 | |||||||||
Adjusted net income per common share assuming dilution(3) | $ | 0.65 | $ | 0.46 | |||||||
| (1)Refers to European Union Medical Device Regulation (“MDR”) and In Vitro Diagnostic Regulation (“IVDR”) related costs. (2) GAAP net loss per common share is calculated using weighted average basic shares outstanding and excludes the impact of outstanding stock awards from the diluted loss per share calculation as their inclusion would have an anti-dilutive effect. (3) Adjusted net income per common share is calculated using weighted average diluted shares outstanding of 51,463 which includes the impact of outstanding stock awards. | |||||||||||
13
| Reconciliation of Adjusted Measures for Year-to-Date FY22 and FY21 | |||||||||||
| (Data in thousands except per share data) | |||||||||||
| Year Ended | |||||||||||
| 4/2/2022 | 4/3/2021 | ||||||||||
| (unaudited) | |||||||||||
| GAAP gross profit | $ | 505,502 | $ | 397,838 | |||||||
| Restructuring and restructuring related costs | 20,068 | 9,708 | |||||||||
| Integration and transaction costs | 5,295 | 6,561 | |||||||||
| Impairment of assets and PCS2 related charges | 4,876 | 23,460 | |||||||||
| Adjusted gross profit | $ | 535,741 | $ | 437,567 | |||||||
| GAAP operating expenses | $ | 424,752 | $ | 308,091 | |||||||
| Deal amortization | (47,414) | (32,830) | |||||||||
| Integration and transaction costs | (16,309) | (11,860) | |||||||||
MDR and IVDR costs(1) | (11,033) | (4,130) | |||||||||
| Restructuring and restructuring related costs | (8,756) | (5,953) | |||||||||
| Litigation-related charges | (1,368) | (897) | |||||||||
| Impairment of assets and PCS2 related charges | (856) | (2,236) | |||||||||
| Gain on divestitures and sale of assets | 9,603 | 32,812 | |||||||||
| Adjusted operating expenses | $ | 348,619 | $ | 282,997 | |||||||
| GAAP operating income | $ | 80,750 | $ | 89,747 | |||||||
| Deal amortization | 47,414 | 32,830 | |||||||||
| Integration and transaction costs | 21,604 | 18,421 | |||||||||
| Restructuring and restructuring related costs | 28,824 | 15,661 | |||||||||
| Impairment of assets and PCS2 related charges | 5,732 | 25,696 | |||||||||
MDR and IVDR costs(1) | 11,033 | 4,130 | |||||||||
| Litigation-related charges | 1,368 | 897 | |||||||||
| Gain on divestitures and sale of assets | (9,603) | (32,812) | |||||||||
| Adjusted operating income | $ | 187,122 | $ | 154,570 | |||||||
| GAAP net income | $ | 43,375 | $ | 79,469 | |||||||
| Deal amortization | 47,414 | 32,830 | |||||||||
| Integration and transaction costs | 21,604 | 21,391 | |||||||||
| Restructuring and restructuring related costs | 28,824 | 15,661 | |||||||||
| Impairment of assets and PCS2 related charges | 5,732 | 25,696 | |||||||||
MDR and IVDR costs(1) | 11,033 | 4,130 | |||||||||
| Litigation-related charges | 1,368 | 897 | |||||||||
| Tax settlement | — | 1,083 | |||||||||
| Gain on divestitures and sale of assets | (9,603) | (32,812) | |||||||||
| Tax impact associated with adjustments | (17,182) | (27,646) | |||||||||
| Adjusted net income | $ | 132,565 | $ | 120,699 | |||||||
| GAAP net income per common share | $ | 0.84 | $ | 1.55 | |||||||
| Adjusted items after tax per common share assuming dilution | 1.74 | 0.80 | |||||||||
| Adjusted net income per common share assuming dilution | $ | 2.58 | $ | 2.35 | |||||||
| (1)Refers to European Union Medical Device Regulation (“MDR”) and In Vitro Diagnostic Regulation (“IVDR”) related costs. | |||||||||||
14
| Projected Fiscal 2023 GAAP and Organic Revenue Growth Rates | |||||
| FY 2023 | |||||
| GAAP Revenue Growth | 5 - 9% | ||||
| Currency impact | 1% | ||||
Organic Revenue Growth(1) | 6 - 10% | ||||
(1) Reflects adjustments to Plasma revenue due to certain strategic exits within the liquid solution business that are projected to be less than 1%. | |||||
15